Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma

BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs. Resistance is often mediated by pathway reactivation through receptor tyrosine kinase (RTK)/SRC-family kinase (SFK) si...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Cell
Autori principali: Girotti, Maria Romina, Lopes, Filipa, Preece, Natasha, Niculescu-Duvaz, Dan, Zambon, Alfonso, Davies, Lawrence, Whittaker, Steven, Saturno, Grazia, Viros, Amaya, Pedersen, Malin, Suijkerbuijk, Bart M.J.M., Menard, Delphine, McLeary, Robert, Johnson, Louise, Fish, Laura, Ejiama, Sarah, Sanchez-Laorden, Berta, Hohloch, Juliane, Carragher, Neil, Macleod, Kenneth, Ashton, Garry, Marusiak, Anna A., Fusi, Alberto, Brognard, John, Frame, Margaret, Lorigan, Paul, Marais, Richard, Springer, Caroline
Natura: Artigo
Lingua:Inglês
Pubblicazione: Cell Press 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297292/
https://ncbi.nlm.nih.gov/pubmed/25500121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2014.11.006
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi